Kala Pharmaceuticals (KALA) Misses Q3 EPS by 1c

Kala Pharmaceuticals (NASDAQ: KALA) reported Q3 EPS of ($0.68), $0.01 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $1.45 million versus the consensus estimate of $3.64 million.

“INVELTYS demonstrated growing demand in the third quarter, with positive feedback from physicians and a continued uptick in prescriptions and market share. Additionally, we made important progress in expanding payor coverage,” said Mark Iwicki, Chief Executive Officer of Kala. “Our STRIDE 3 Phase 3 clinical trial for EYSUVISTM (KPI-121 0.25%), our product candidate for dry eye disease, continues to enroll and we are targeting topline data in the first quarter of 2020. We expect that data from this trial will serve as the basis for our resubmission of the EYSUVIS New Drug Application to the U.S. Food and Drug Administration.”

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• BIG3 Basketball to go public via Graf Global merger at $290 million
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist